Transforming growth factor and neutralizing antibodies in subglottic stenosis

Annals of Otology, Rhinology and Laryngology

Volumn 110, Issue 5 I, 2001, Pages 393-400

  Dillard, David G ^a   Gal, Anthony A ^a   White, Stephen ^a   Roman Rodriguez, Jesse ^a   Jacobs, Ian N ^b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Subglottic stenosis; Transforming growth factor beta 1

Indexed keywords

FIBRONECTIN; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVICE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OPTICAL DENSITY; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBGLOTTIC STENOSIS;

EID: 0035041011     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940111000501     Document Type: Article

References (23)

1. Parkin JL, Stevens MH, Jung AL. Acquired and congenital subglottic stenosis in the infant. Ann Otol Rhinol Laryngol 1976;85:573-81.
2. Papsidero MJ, Pashley NRT. Acquired stenosis of the upper airway in neonates. An increasing problem. Ann Otol Rhinol Laryngol 1980;89:512-4.
3. Sherman JM, Lowitt S, Stephenson C, Ironson G. Factors influencing acquired subglottic stenosis in infants. J Pediatr 1986;109:322-7.
4. Orlowski JP, Ellis NG, Amin NP, Crumrine RS. Complications of airway intrusion in 100 consecutive cases in a pediatric ICU. Crit Care Med 1980;8:324-31.
5. Alexander KJ, Schuller DE. Ferret model for acquired subglottic stenosis. Ann Otol Rhinol Laryngol 1989;98:910-5.
6. Whited RE. A prospective study of laryngotracheal sequelae in long-term intubation. Laryngoscope 1984;94:367-77.
7. Hom DB. Growth factors in wound healing. Otolaryngol Clin North Am 1995;28:933-53.
8. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-71.
9. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990;346: 371-4.
10. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6.
11. Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R. Human transforming growth factor-β3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-β1 and β2. Mol Endocrinol 1989;3:1977-86.
12. Roberts AB, Sporn MB. The transforming growth factors. In: Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors. Berlin, Germany: Springer Verlag, 1990: 419-72.
13. Sullivan KM, Lorenz HP, Meuli M, Lin RY, Adzick NS. A model of scarless human fetal wound repair is deficient in transforming growth factor beta. J Pediatr Surg 1995;30:198-203.
14. Krummel TM, Michna BA, Thomas BL, et al. Transforming growth factor beta (TGF-β) induces fibrosis in a fetal wound model. J Pediatr Surg 1988;23:647-52.
15. Lin RY, Sullivan KM, Argenta PA, Meuli M, Lorenz HP, Adzick NS. Exogenous transforming growth factor-beta amplifies its own expression and induces scar formation in a model of human fetal skin repair. Ann Surg 1995;222:146-54.
16. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxi-dase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
17. Flanders KC, Thompson NL, Cissel DS, et al. Transforming growth factor-β1 : histochemical localization with antibodies to different epitopes. J Cell Biol 1989;108:653-60.
18. Chen C, Ku DN, Kikeri D, Lumsden AB. Tenascin: a potential role in human arteriovenous PTFE graft failure. J Surg Res 1996;60:409-16.
19. Svetic A, Finkelman FD, Jian YC, et al. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol 1991;147:2391-7.
20. Wynn TA, Eltoum I, Cheever AW, Lewis FA, Gause WC, Sher A. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J Immunol 1993;151:1430-40.
21. Shah M, Foreman DM, Ferguson MWJ. Neutralisation of TGF-β1 and TGF-β2 or exogenous administration of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108:985-1002.
22. Kane CJM, Hebda PA, Mansbridge JN, Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing. J Cell Physiol 1991;148:157-73.
23. Sylvester KG, Yang EY, Cass DL, Crombleholme TM, Adzick NS. Fetoscopic gene therapy for congenital lung disease. J Pediatr Surg 1997;32:964-9.